DRUG · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $0.9B · 25 employees
84
SEC Filings
$67.6
Close 2026-07-02
25
Employees
Business Summary
Bright Minds Biosciences Inc. is a biotechnology company developing innovative treatments for neurological and psychiatric disorders. Its pipeline includes novel serotonergic agonists targeting 5-HT2C and 5-HT2A receptor subtypes. Lead product BMB-101 is a 5-HT2C selective agonist in Phase 2 clinical trials for drug-resistant epilepsies including Dravet Syndrome. Other candidates BMB-201 and BMB-202 are selective 5-HT2A agonists in IND-enabling studies for neuropsychiatry and neurology indications.
Latest Stock Quote
DRUG 2026-07-02 $67.6
O:$67 H:$69.5 L:$65.83 Vol:0.2M VWAP:$67.3694
origin leaf: null
84 total filings indexed. 84 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Look up DRUG using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on DRUG, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/DRUG (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.